DISRUPT THERAPEUTICS
Contact information
Disrupt Therapeutics, S.L.
Patrick Tresserras - CEO
C/ Dr. Aiguader, 88 - Barcelona Biomedical Research Park
Barcelona - 08003
Barcelona
Areas of activities
- Biodrugs
- Drug delivery
- Drug development
- Substance abuse
- Analgesia & Pain
- Central nervous system
Commissions
Disrupt Therapeutics is a biotechnology company dedicated to developing new drugs for the treatment of cannabis use disorder.
Products and services
DRT-101 is an orally administered peptide-based drug designed to modulate the neurobiological mechanisms involved in the development of cannabis addiction.
Areas of interest for future collaborations
1. R&D in substance use disorders
2. R&D in therapeutics aimed at mitigating the side effects of medical cannabis
Biotech Sanitaria
| Product / Service | Type | Therapeutic area | Aplication | Development phase |
|---|---|---|---|---|
| DRT-101 | Biodrugs/ Drugs | Abuso de sustancias, Analgesia / Dolor, Sistema nervioso central | Pharmaceutical industry, biotechnology companies, and the neuropharmacology and mental health sectors. The primary application is in the treatment of cannabis use disorder, while the mechanism of action also enables safer medical cannabis use by preventing the development of addiction and memory impairment. Potential applications further extend to innovative therapies for psychiatric disorders, in collaboration with academic, clinical, and industrial partners. | Preclinical |